RxDoctor Payments Data

Caroline Murphy

Psychiatric/Mental Health · Binghamton, NYNPI 1356725774

Payments from drug & device makers

$3,548in general payments, 2019–2025

Across 150 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$387
  • Otsuka America Pharmaceutical, Inc.$266
  • Corium, LLC$152
  • Alkermes, Inc.$89
  • Sunovion Pharmaceuticals Inc.$75
  • plus $219 from 7 others

What the payments were for

  • Food & beverage$3,531100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,548 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$6,751
Medicare patients
12
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl53$78,284
Abilify AsimtufiiAripiprazole11$53,840
RexultiBrexpiprazole29$44,788
CaplytaLumateperone Tosylate13$26,356
LatudaLurasidone Hcl14$24,750
TrintellixVortioxetine Hydrobromide11$6,136
QelbreeViloxazine Hcl12$5,656
Lisdexamfetamine Dimesylate15$4,899
Clonidine32$3,182
Hydroxyzine Hcl127$2,613
Quetiapine Fumarate ErQuetiapine Fumarate14$2,558
Prazosin Hcl95$1,848
Lamotrigine180$1,536
Quetiapine Fumarate65$1,470
Duloxetine Hcl49$1,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti$266$98,62840 claims
AbbVieVraylar$2,360$78,28453 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$44$26,35613 claims
Sunovion Pharmaceuticals Inc.Latuda$75$24,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →